Receptor Activator of Nuclear Factor kB Ligand (RANKL) Is a Key Molecule of Osteoclast Formation for Bone Metastasis in a Newly Developed Model of Human Neuroblastoma

Toshimi Michigami, Miyuki Ibara-Watanabe, Miwa Yamazaki, and Keiichi Ozono

Department of Environmental Medicine, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka 594-1101, Japan

ABSTRACT

Neuroblastoma originates from neural crest cells and is the most common extracranial solid tumor in childhood. Bone metastasis in neuroblastoma is an unfavorable prognostic factor even with intensive therapy. In the present study, we screened four cell lines of human neuroblastoma (NB-1, NB-16, NB-19, and NB-6) for tumorigenicity and metastatic capacity in nude mice and found that NB-19 cells caused osteolytic lesions after s.c. injection into mice. To detect micrometastases in the host tissue, we performed two kinds of PCR-based metastasis assays: (a) genomic PCR assay using the primers for human genome-specific Alu sequence; and (b) reverse transcription-nested PCR assay that detects the expression of tyrosine hydroxylase, a marker specific for neuroblastoma. The results of these PCR assays revealed the colonization of human neuroblastoma cells in the bone marrow of the mice that had received the s.c. injection of NB-19 cells. Because osteoclastic bone resorption has been reported to play important roles in osteolysis in some cancers such as breast cancer, we next examined the osteoclast (OC)-inducing activity of NB-19 cells using a coculture system in which NB-19 cells were cultured with murine bone marrow cells containing OC precursors and stromal cells. NB-19 cells induced tartrate-resistant acid phosphatase-positive multinucleated OC-like cells without requirement of 1,25-dihydroxyvitamin D3 or other osteoclastogenic stimulators. To investigate the factors involved in the osteoclastogenesis in the coculture of mouse marrow cells and NB-19 cells, we performed reverse transcription-PCR analysis and revealed the increased expression of receptor activator of nuclear factor kB ligand (RANKL) in the coculture compared with the culture of bone marrow cells alone. Interleukin-1α and cyclooxygenase-2 expression in the murine marrow cells was also increased in the presence of NB-19 cells. To further study the role of RANKL in the OC-like cell formation in the coculture of NB-19 cells and murine marrow cells, an expression vector encoding the active portion of the murine osteoprotegerin, which is the native inhibitor of RANKL action, was constructed and introduced into COS-7 cells. The conditioned media of the COS-7 cells transfected with the osteoprotegerin expression vector effectively blocked OC-like cell formation in the coculture of the bone marrow cells and NB-19 cells. These results suggested that in the bone microenvironment of NB-19-bearing mice, the stimulated expression of RANKL plays an important role in OC formation, leading to osteolytic bone metastasis.

INTRODUCTION

Neuroblastoma originates in cells of the neural crest and is the most common extracranial solid tumor in childhood (1–4). Prognosis in neuroblastoma patients is strongly related to patient age, tumor stage, site at diagnosis, and biological features of tumor cells (5–8). Patients over 1 year of age often present with advanced disease, and bone marrow metastases are associated with a poor prognosis despite high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Bone is one of the target organs of metastasis in advanced neuroblastoma, and the presence of bone metastasis is responsible for a poor prognosis. One possible reason for this is the difficulty in treating cancer cells that are colonizing the bone/bone marrow microenvironment. According to the staging system of neuroblastoma proposed by the Children’s Cancer Study Group, patients with bone metastasis are classified as stage IV without regard to other clinical manifestations and have a survival rate of ~7% (9). In contrast, the patients with stage IV-S disease, where the tumor does not cross the midline despite the presence of metastasis to liver, skin, or bone marrow, show a rather favorable prognosis, and the survival rate has been reported to be ~75% (10, 11). These data suggest the urgent need to develop an effective bone-targeting therapy in neuroblastoma.

In some cancers such as breast cancer and myeloma as well, bone metastasis causes clinical complications including pain, pathological fractures, and nerve compression (12). In the case of breast cancer, the role of osteoclastic bone resorption enhanced by the secretion of PTHrP has been demonstrated in the development of bone metastasis (13), and adjuvant therapy with inhibitors of the osteoclastic bone resorption including bisphosphonates was proven to be beneficial (14–17). In neuroblastoma, however, the mechanisms involved in the bone metastasis have not been elucidated. In addition, because treatment with bisphosphonates may have adverse effects on bone growth in infants and children, other therapies may be required to treat childhood patients with neuroblastoma, although bisphosphonates have proven to be effective in treating bone complications in breast cancer patients and myeloma patients (14, 18).

The interaction between cancer cells and the bone marrow microenvironment plays an important role in bone metastasis. In the case of breast cancer, it is reported that estrogen-independent MDA-MB-231 cells respond to produce more PTHrP in the bone microenvironment when exposed to transforming growth factor β, which is stored in bone matrix and released by osteoclastic bone resorption (19). The increased production of PTHrP may accelerate the osteoclastic destruction of bone, creating the space for cancer proliferation in bone. Another line of studies using the murine mammary tumor cell line MMTh065062 has demonstrated that PGE2 plays a role in in vitro osteoclastogenesis in a coculture system of tumor cells and bone marrow cells, although this tumor cell line does not possess metastatic potential in vivo (20).

Very recently, RANKL, a novel cytokine also known as OPG ligand, OC differentiating factor, and TNF-related activation-induced cytokine, has been identified as being critical to OC recruitment (21–24). RANKL, expressed in bone marrow stromal cells that support OC differentiation, encodes a 316-aa type II transmembrane protein and belongs to the TNF ligand family. RANKL exerts its...
effects through its cognate receptor, RANK, which is expressed on the OC precursors (25). OPG is a soluble OC-inhibitory molecule that is a member of the TNF receptor family, along with RANK (23). OPG binds to RANKL as a decoy receptor and inhibits OC recruitment by interrupting the interaction between RANKL and RANK. There is no doubt that RANKL is a key regulator of osteoclastogenesis because RANKL-knock out mice show severe osteopetrosis and a defect of tooth eruption as a result of an inability of osteoblasts to support osteoclast formation (26). It has also been revealed that a variety of extracellular factors including 1,25-dihydroxyvitamin D₃, parathyroid hormone, PGE₂, IL-1, and IL-6 induce osteoclastogenesis through the stimulation of RANKL expression in bone marrow stromal cells. It is likely that increased cytokine production may cause the stimulated RANKL expression and accelerate osteoclastic bone destruction in the bone marrow microenvironment where cancer cells are colonized.

To study the mechanisms of metastasis and develop a new strategy for treating patients with cancer, appropriate animal models are required. However, there are few good models of bone metastasis; one example is the breast cancer model by intracardiac inoculation of human breast cancer cells in the bone marrow of the host mice, we performed RT-PCR for Tyrosine Hydroxylase.

**MATERIALS AND METHODS**

**Cell Culture.** Human neuroblastoma cell lines NB-16 and NB-19 were provided by Riken Cell Bank (Saitama, Japan). NB-1 and NH-6 were obtained from Human Science Research Resources Bank (Osaka, Japan). NB-16, NB-19, and NB-1 cells were maintained in RPMI 1640 (Nikken, Kyoto, Japan) supplemented with 10% FCS (Life Technologies, Inc., Grand Island, NY) and antibiotics (Life Technologies, Inc.), and NH-6 cells were cultured in α-MEM (Nikken) with 10% FCS and antibiotics under a 5% CO₂ atmosphere.

**Tumor Cell Injection into Nude Mice.** Animal protocols were approved by the Institutional Animal Care and Use Committee at Osaka Medical Center for Cancer and Research Institute for Maternal and Child Health. Four-week-old female nude mice (BALB/cA nu/nu) were supplied by Clea Japan (Tokyo, Japan) and maintained under pathogen-free conditions. For heterotransplantation, NB-16 and NB-1 cell lines were mechanically detached from the culture dish, and NB-19 and NH-6 cell lines were harvested by treatment with 0.25% trypsin-0.5 mM EDTA solution for 2 weeks at room temperature with gentle stirring. Sections were made by the conventional method and stained with H&E.

**Micrometastasis Assay Based on Genomic PCR for Alu Sequence and RT-PCR for Tyrosine Hydroxylase.** To detect the micrometastases of human neuroblastoma cells in the bone marrow of the host mice, we performed a PCR-based metastasis assay using the amplification of Alu sequences that are specific to the human genome (30). Genomic DNA was isolated from the bone marrow of tumor-bearing mice and control mice using Trizol reagent (Life Technologies, Inc.) following the manufacturer’s instructions. Specific primers for human Alu sequences were Alu-sense (5′-ACGCCTGTAATCCCAGGTA-3′) and Alu-antisense (5′-TCGCCCAGGCTGGAGTGCA-3′), which produced a band of 224 bp (30). PCR was carried out using 100 ng of genomic DNA.

**Table 2**

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Mean diameter (mm; mean ± SE)</th>
<th>Mice with mass (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NB-1</td>
<td>6.4 ± 0.9</td>
<td>80</td>
</tr>
<tr>
<td>NB-16</td>
<td>15.6 ± 2.4</td>
<td>100</td>
</tr>
<tr>
<td>NB-19</td>
<td>19.6 ± 1.1</td>
<td>100</td>
</tr>
<tr>
<td>NH-6</td>
<td>9.7 ± 0.4</td>
<td>100</td>
</tr>
</tbody>
</table>

The presence of NB-19 cells in murine bone marrow cells induced micrometastasis to distant organs (28, 29). Tumorigenicity of each cell line in mice was evaluated using the mass size 8 weeks after tumor cell injection.

**Histological Examination.** Bones of tumor-bearing mice and control mice were fixed in 10% buffered formalin, followed by decalcification in 14% EDTA solution for 2 weeks at room temperature with gentle stirring. Sections were made by the conventional method and stained with H&E.

**Table 1 Primers used in the RT-PCR analysis**

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequences (5′→3′)</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Actin Sense</td>
<td>GTGGGGCCGCCCCAGGCACCA</td>
<td>548</td>
</tr>
<tr>
<td>Human IL-α Sense</td>
<td>CTCCCTTAAGTGCACCGCAGATTTC</td>
<td>308</td>
</tr>
<tr>
<td>Human IL-α Antisense</td>
<td>TGGATCCAGGGGAACACTG</td>
<td>816</td>
</tr>
<tr>
<td>Murine IL-β Sense</td>
<td>ATGGCACTCTCCAGGAGCTTC</td>
<td>320</td>
</tr>
<tr>
<td>Murine IL-β Antisense</td>
<td>TTATGAGAACACAAATTTGATGGTAACCTCAGT</td>
<td>810</td>
</tr>
<tr>
<td>Human IL-6 Sense</td>
<td>TGGAGTCCACAGGAAGGATGCTAAGG</td>
<td>155</td>
</tr>
<tr>
<td>Human IL-6 Antisense</td>
<td>TCTGACCACAGTGGAAGATGCCAC</td>
<td>639</td>
</tr>
<tr>
<td>Murine TNF-α Sense</td>
<td>ATGGAATCTCTCCACAAGGC</td>
<td>249</td>
</tr>
<tr>
<td>Murine TNF-α Antisense</td>
<td>AGGGATTAGAAGTTCCCAA</td>
<td>271</td>
</tr>
<tr>
<td>Murine TNF-β Sense</td>
<td>ATGGAACTCCTTCTCCACAAGC</td>
<td>579</td>
</tr>
<tr>
<td>Murine TNF-β Antisense</td>
<td>AGGAACCTGGGAGTAGAACA</td>
<td>820</td>
</tr>
<tr>
<td>Murine RANKL Sense</td>
<td>ATGGAATCTCTCCACAAGC</td>
<td>750</td>
</tr>
<tr>
<td>Murine OPG Sense</td>
<td>GGAAGCTGGAACAACCTCTCCAAAG</td>
<td>560</td>
</tr>
</tbody>
</table>

**Micrometastasis Assay Based on Genomic PCR for Alu Sequence and RT-PCR for Tyrosine Hydroxylase.** To detect the micrometastases of human neuroblastoma cells in the bone marrow of the host mice, we performed a PCR-based metastasis assay using the amplification of Alu sequences that are specific to the human genome (30). Genomic DNA was isolated from the bone marrow of tumor-bearing mice and control mice using Trizol reagent (Life Technologies, Inc.) following the manufacturer’s instructions. Specific primers for human Alu sequences were Alu-sense (5′-ACGCCTGTAATCCCAGGTA-3′) and Alu-antisense (5′-TCGCCCAGGCTGGAGTGCA-3′), which produced a band of 224 bp (30). PCR was carried out using 100 ng of genomic DNA.

**Table 2**

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Mean diameter (mm; mean ± SE)</th>
<th>Mice with mass (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NB-1</td>
<td>6.4 ± 0.9</td>
<td>80</td>
</tr>
<tr>
<td>NB-16</td>
<td>15.6 ± 2.4</td>
<td>100</td>
</tr>
<tr>
<td>NB-19</td>
<td>19.6 ± 1.1</td>
<td>100</td>
</tr>
<tr>
<td>NH-6</td>
<td>9.7 ± 0.4</td>
<td>100</td>
</tr>
</tbody>
</table>
DNA as template and recombinant Taq DNA polymerase (Takara Syuzo, Kyoto, Japan) under the following thermocycling conditions: an initial denaturation step of 94°C for 4 min; 25 cycles comprised of 94°C for 30 s, 60°C for 45 s, and 72°C for 45 s; and a final extension step of 72°C for 7 min.

We also performed another micrometastasis assay using RT-PCR that amplified cDNA of tyrosine hydroxylase, a specific marker for neuroblastoma (31). Total RNA was extracted from the bone marrow of the mice bearing each cell line using Trizol reagent at the same time as the genomic DNA was obtained. Two μg each of total RNA were then reverse transcribed using random hexamers (Promega, Madison, WI) and SuperScript II reverse transcriptase (Life Technologies, Inc.). For PCR, the following primers were used:

(a) hTH340F (sense), 5′-AGCCAAAATCCACCATCTAG-3′;
(b) hTH528F (sense), 5′-TGTCAGAGCTGGACAAGTGT-3′;
(c) hTH826R (antisense), 5′-GATATTGTCTTCCCGGTAGC-3′;
and (d) hTH866R (antisense), 5′-TGCGCTCCTTCAGGAAGCGG-3′. The first-round PCR was performed using the primer set of hTH340F and hTH866R, which was expected to amplify a 526-bp fragment in the presence of tyrosine hydroxylase mRNA. Thirty cycles of amplification were carried out with 94°C for 30 s, 55°C for 1 min, and 72°C for 1 min. For the second-round PCR, the primer set of hTH528F and hTH826R was used with 2-μl aliquots of the first-round PCR products (20 μl) as template, amplifying a 298-bp fragment. The thermocycling program for the second-round PCR was the same as that used for the first-round PCR.

**OC-like Cell Formation Assay.** OC-like cell formation assay was carried out following the methods originally described by Takahashi et al. (32), with some modifications. Murine bone marrow cells were collected aseptically from C57BL/6N mice (Clea Japan). The collected cells were washed and resuspended in α-MEM supplemented with 10% FCS (HyClone, Logan, UT), and the cell suspension was incubated in 10-cm culture dishes (Becton Dickinson Labware, Franklin Lakes, NJ) at 37°C for 2 h. After the incubation, the nonadherent cells were collected and plated onto 48-well plates at a density of 1 × 10⁶ cells/well with various numbers of NB-19 cells (0–1 × 10⁴ cells/well) and cultured for 6 days in α-MEM supplemented with 10% FCS in the absence of 1,25-dihydroxyvitamin D or any other OC-inducing reagent. When the cultures were terminated, the cells were fixed and stained for TRAP activity using a commercial kit (Sigma, St. Louis, MO). The TRAP(+)MNCs containing two or more nuclei were counted as OC-like cells.

**RT-PCR Analysis for Cytokines, COX-2, RANKL, and OPG.** To examine what kind of cytokines were involved in the TRAP(+) MNC formation in the coculture of murine bone marrow cells and NB-19 neuroblastoma cells, RT-PCR analysis was performed. Murine bone marrow cells (1 × 10⁷ cells/well) and NB-19 cells (1 × 10⁵ cells/well) were plated together or separately to each well of 6-well plates and cultured for 6 days in α-MEM supplemented with 10% FCS in the absence of 1,25-dihydroxyvitamin D or other osteoclastogenic stimulators. When the cultures were terminated, total RNA was ex-

---

**Fig. 1.** A, X-ray of the knee of a nude mouse that had received the s.c. injection of NB-19 cells. Cells (2 × 10⁷) were injected s.c. into the right dorsal area of 4-week-old female nude mice, and the mice were X-rayed 8 weeks later. The arrow indicates the osteolytic lesion. B, X-ray of the knee of an age-matched control mouse that did not receive the tumor cell injection.

**Fig. 2.** H&E-stained sections of tibiae in NB-19-bearing mice (A) and non-tumor-bearing control mice (B). In NB-19-bearing mice, trabecular volume was decreased compared with that of control mice.
osteoclast formation induced by neuroblastoma

Fig. 3. PCR-based metastasis assay using the bone marrow obtained from NB-19-bearing mice. Genomic DNA and total RNA were extracted from the nude mice that had received a s.c. injection of neuroblastoma cells and subjected to genomic PCR for human-specific Alu sequence and reverse transcription-nested PCR for tyrosine hydroxylase, respectively. Lane 1, bone marrow from a NB-1-bearing mouse; Lane 2, bone marrow from a NB-16-bearing mouse; Lane 3, bone marrow from a NB-19-bearing mouse; Lane 4, bone marrow from a NIH-6-bearing mouse.

Fig. 4. TRAP(+)MNC formation observed in the coculture of murine bone marrow cells and NB-19 human neuroblastoma cells and the effect of recombinant OPG. Murine bone marrow cells (1 x 10⁵ cells/well) were plated with (A) or without (B) NB-19 cells (1 x 10⁵ cells/well) onto 48-well culture plates and cultured for 6 days in the absence of any osteoclastogenic stimulator. When the culture was terminated, the cells were stained for TRAP activity. The arrow indicates the TRAP(+)MNC formed in the coculture of marrow cells and NB-19 cells. Original magnification was ×100 in both A and B. In C, murine bone marrow cells (1 x 10⁵/well) were plated onto 48-well culture plates with or without NB-19 cells (1 x 10⁵ cells/well) and cultured for 6 days in the presence or absence of the conditioned media (CM) harvested from the COS-7 cells transfected with the OPG expression vector or the empty vector (EV). After culture for 6 days, the numbers of TRAP-positive cells with two or more nuclei were determined. Data are expressed as the means ± SE of triplicate cultures. * significantly different from the value in the culture of marrow cells and NB-19 cells treated with the conditioned media from empty vector transfectants (P < 0.05).

Results

Development of a Neuroblastoma Bone Metastasis Model. Table 2 summarizes the tumorigenicity of the four cell lines of human neuroblastoma examined as described in “Materials and Methods.” NB-19 and NB-16, originating from the involved bone marrow of patients with advanced neuroblastoma, exhibited stronger tumorigenicity than NB-1 and NH-6, which were established from the primary sites of the disease. Interestingly, NB-19-bearing mice showed splenomegaly. Radiological examination of NB-19-bearing mice revealed the development of osteolytic lesions 8 weeks after tumor cell injection (Fig. 1). Of the 10 mice that had been inoculated...
with NB-19 cells, all of them had a mass at the inoculation site, and 7 of them exhibited osteolytic lesions detectable by X-ray. The total number of these regions was 14 (5 lesions in right tibiae, 6 lesions in left tibiae, and 3 lesions in left femurs), and the diameter of these lesions was 1.71 ± 0.67 mm (mean ± SD). In the histological analysis, although the decrease in trabecular volume was obvious in NB-19-bearing mice, massive metastasis was not apparent (Fig. 2). To confirm the presence of NB-19 cells in the bone marrow of the host animals, we performed genomic PCR for Alu sequences using the genomic DNA extracted from the tumor-bearing mice. Specific signals were detected when DNA from the bone marrow of NB-19-bearing mice was used as template, but not when DNA obtained from the bone marrow of nude mice bearing other cell lines was used (Fig. 3). In the RT-PCR assay for tyrosine hydroxylase as well, specific signals were detected only when the RNA from the NB-19-bearing mice was used as template (Fig. 3), confirming the presence of human neuroblastoma cells in the bone marrow of NB-19-bearing mice.

The sensitivities of these PCR-based assays were tested, and it was found that 100 neuroblastoma cells in one million murine cells were detectable by these assays (data not shown).

**TRAP(+)MNC Formation in the Coculture of Murine Bone Marrow Cells and NB-19 Human Neuroblastoma Cells.** Murine bone marrow cells were cultured for 6 days in the presence or absence of NB-19 cells, and the number of TRAP(+)MNCs was determined. In the absence of NB-19 cells, the murine bone marrow cells did not form TRAP(+)MNCs without the addition of OC-inducing reagents such as 1,25-dihydroxyvitamin D (Fig. 4B). In the presence of NB-19 cells, a number of TRAP(+)MNCs were formed even in the absence of an osteoclastogenesis stimulator (Fig. 4A).

**RT-PCR Analysis for the Factors Involved in OC-like Cell Formation Induced by NB-19 Cells.** To identify the soluble factor(s) involved in the TRAP(+)MNC formation in this system, RT-PCR analysis was performed, and we detected that murine IL-1α expression was stimulated in the coculture of bone marrow cells and NB-19 cells compared with the marrow cells cultured in the absence of NB-19 cells (Fig. 5). These PCR products were revealed to be identical to murine IL-1α cDNA by sequencing analysis (data not shown). No signals were detected when the primer set for human IL-1α was used (data not shown). Murine TNF-α and TNF-β were detected in the culture of murine bone marrow cells alone and in the coculture of murine bone marrow cells and NB-19 cells at similar levels but were not detected in the culture of NB-19 alone (Fig. 5).

Because IL-1α has been reported to increase PG production, we also examined the expression of COX-2 in this coculture system. In the RT-PCR analysis, the expression of COX-2 appeared to be increased in the coculture of NB-19 cells and bone marrow cells compared with the culture of bone marrow cells alone (Fig. 5). The PCR product amplified from the cDNA of the coculture was subjected to cloning into pT7-Blue vector (Novagen), followed by sequencing. All of the eight clones examined were identical to the cDNA for murine COX-2 (data not shown).

RANKL expression was up-regulated in the coculture of NB-19 and marrow cells compared with the culture of marrow cells alone, whereas the expression level of OPG was unchanged (Fig. 5). Sequencing analysis revealed that these PCR products were identical to murine sequences (data not shown).

**Biological Activities of Recombinant RANKL and OPG.** The biological activity of recombinant RANKL and OPG was examined in murine bone marrow culture. In the presence of recombinant human M-CSF (10 ng/ml; Genzyme/Techne, Minneapolis, MN), the conditioned media from the RANKL-transfected COS-7 cells stimulated TRAP(+)MNC formation in a dose-dependent manner (Fig. 6, A and C). Crude conditioned media harvested from the COS-7 cells transfected with the OPG expression vector or empty vector pFLAG-CMV-1 were added to the murine bone marrow culture in the presence of 10 ng/ml M-CSF and the conditioned media from the RANKL-transfected cells (20% concentration of the culture media). The conditioned media from OPG-transfected cells inhibited RANKL-induced TRAP(+)MNC formation in a dose-dependent manner, whereas the conditioned media from empty vector-transfected cells did not (Fig. 6, B and D). These data suggested that recombinant RANKL and recombinant OPG prepared in the study were biologically active.

**Recombinant OPG Inhibited TRAP(+)MNC Formation in the Coculture of Murine Bone Marrow Cells and NB-19 Neuroblastoma Cells.** Because RT-PCR analysis suggested the involvement of RANKL in TRAP(+)MNC formation in the coculture of marrow cells and NB-19 cells, we next examined whether the recombinant OPG could inhibit the TRAP(+)MNC formation in this coculture system. Crude conditioned media harvested from the COS-7 cells transfected with the OPG expression vector or the empty vector were added to the coculture of NB-19 cells and marrow cells, and the cells were cultured for 6 days in the absence of any osteoclastogenic stimulator such as 1,25-dihydroxyvitamin D. The conditioned media from the OPG-transfected cells inhibited TRAP(+)MNC formation in the coculture of NB-19 cells and marrow cells, whereas the conditioned media from the empty vector-transfected cells did not (Fig. 4C).
DISCUSSION

In the present study, we screened four cell lines of human neuroblastoma for tumorigenicity and bone metastatic capacity in immunocompromised nude mice, and we detected micrometastasis of NB-19 cells, which had originally been obtained from the bone marrow of a patient with stage IV neuroblastoma (34). After s.c. injection into nude mice, NB-19 cells reproducibly developed osteolytic lesions in the long bones detectable by radiographs. Because bone metastasis in neuroblastoma patients is also usually osteolytic, the radiological manifestation in NB-19-bearing mice is clinically relevant.

In addition to the osteolytic lesions revealed in radiography, two different PCR-based assays detected micrometastasis of NB-19 cells in the host bone marrow. One of the assays was based on the genomic PCR amplification of Alu sequences specific to the human genome, which had been previously used in the chick embryo metastasis model by Kim et al. (30). The other assay, reverse transcription-nested PCR for tyrosine hydroxylase, has been used to detect occult neuroblastoma cells in the bone marrow and peripheral blood of patients on therapy (31). In both assays, the signals were detected in the bone marrow of NB-19-bearing mice but not in those of the control animals, confirming the presence of human neuroblastoma cells in the bone marrow of NB-19-bearing mice. Neither of the assays detected signals when bone marrow obtained from mice bearing one of the other three cell lines (NB-1, NB-16, and NH-6) was used as the source of the template.

A number of reports have demonstrated that osteoclastic bone resorption is important to the development of bone metastasis in some cancer types including breast cancer, lung cancer, and prostate cancer (35). These cancers induce OC formation via secretion of PTHrP, IL-1α, or PGE₂ by themselves (13, 20, 36). Consistent with the role of bone resorption in cancer metastasis, antiresorption therapy such as administration of bisphosphonates or anti-PTHrP neutralizing antibody was reported to be effective in an animal model of breast cancer.
in which direct intracarotid injection of MDA-MB-231 cells was performed on nude mice (13, 37).

To study the OC-forming activity induced by the presence of NB-19 cells in the host bone marrow, we performed an *in vitro* osteoclastogenesis assay using a murine bone marrow culture system. In this assay, OC-like TRAP+ iMNCs were formed in the coculture of NB-19 neuroblastoma cells and murine bone marrow cells without the requirement for any osteoclastogenen stimulator, including 1,25-dihydroxyvitamin D and PTHrP. These results suggested that production of some OC-inducing activity is involved in osteolysis in NB-19-bearing mice, which was triggered by the presence of neuroblastoma cells in the host bone marrow.

We further examined which factors were involved in OC-like cell formation induced by the presence of NB-19 cells. We found that the expression of IL-1α was stimulated in the coculture of NB-19 cells and murine bone marrow cells compared with the cultures of NB-19 alone or marrow cells alone. IL-1α has been reported to induce COX-2, which is the key enzyme for PGE2 synthesis. PGE2 is known as a potent inducer of OC formation (38), and recent studies have revealed that PGE2 is one of the inducers for RANKL (22). Consistent with these findings, the expressions of both COX-2 and RANKL as well as IL-1α were up-regulated in the coculture of NB-19 cells and murine bone marrow cells compared with cultures of NB-19 or marrow cells alone. The data suggested that the presence of NB-19 cells stimulated the expression of IL-1α, COX-2, and RANKL in the murine marrow cells.

In the present study, the significant role of RANKL in the osteolysis found in our model was enhanced by the blockade of OC-like cell formation by recombinant OPG in the coculture of NB-19 cells and murine bone marrow cells. These results may lead to a new therapeutic approach to bone metastasis in neuroblastoma such as the administration of recombinant OPG or gene therapy using OPG expression vector. Recombinant RANKL constructed in the study required M-CSF to induce osteoclastogenesis *in vitro*, which was consistent with the previous reports (39).

Cell-cell interaction via adhesion molecules between tumor cells and bone marrow stromal cells also appears to play a role in bone metastasis. The overexpression of integrin αvβ3 promoted the bone metastasis of Chinese hamster ovary cells, suggesting that the interaction between integrin αvβ3 and vascular cell adhesion molecule 1 expressed on the bone marrow stromal cells is important in bone metastasis (40). The Chinese hamster ovary cells overexpressing integrin αvβ3 were also reported to stimulate OC-like cell formation *in vitro* (41). However, NB-19 cells did not express integrin αvβ3 (data not shown). Some surface molecule other than integrin αvβ3 might be responsible for osteoclastogenesis and metastatic osteolysis in neuroblastoma.

In conclusion, we have developed a unique model of osteolytic bone metastasis where the presence of human neuroblastoma NB-19 cells in bone marrow was proven by two kinds of PCR-based assays 8 weeks after the s.c. injection of tumor cells into nude mice. Tumor-host cell interaction between NB-19 cells and murine bone marrow cells resulted in the increased expressions of IL-1α, COX-2, and RANKL, leading to OC formation. Recombinant OPG was capable of blocking this OC formation, demonstrating the critical role of RANKL in osteolysis induced by neuroblastoma cells.

ACKNOWLEDGMENTS

We thank Tomoko Hayashi for secretarial assistance.

REFERENCES

31. Miyajima, Y., Horibe, K., Fukuda, M., Matsumoto, K., Numata, S., Mori, H., and Kato, K. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer (Phila.), 77: 1214–1219, 1996.
Updated version  Access the most recent version of this article at:  
http://cancerres.aacrjournals.org/content/61/4/1637

Cited articles  This article cites 34 articles, 6 of which you can access for free at:  
http://cancerres.aacrjournals.org/content/61/4/1637.full#ref-list-1

Citing articles  This article has been cited by 12 HighWire-hosted articles. Access the articles at:  
http://cancerres.aacrjournals.org/content/61/4/1637.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.